LivaNova (NASDAQ:LIVN) Downgraded by Zacks Research to “Hold”

Zacks Research cut shares of LivaNova (NASDAQ:LIVN) from a strong-buy rating to a hold rating in a report published on Wednesday,Zacks.com reports.

Other analysts have also recently issued reports about the stock. Weiss Ratings raised shares of LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday. Stifel Nicolaus set a $85.00 target price on LivaNova in a research report on Wednesday, August 5th. KeyCorp increased their target price on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, June 22nd. Freedom Capital upgraded LivaNova to a “hold” rating in a report on Tuesday, June 30th. Finally, Needham & Company LLC boosted their price target on LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Six research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $83.50.

LivaNova Stock Performance

LivaNova stock opened at $78.21 on Wednesday. The stock’s 50-day moving average is $80.56 and its 200-day moving average is $71.83. The company has a market cap of $4.31 billion, a price-to-earnings ratio of 23.14 and a beta of 0.86. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.21. LivaNova has a 12 month low of $48.82 and a 12 month high of $85.76.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.17. The business had revenue of $390.59 million for the quarter, compared to analyst estimates of $380.50 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The company’s revenue was up 10.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.05 EPS. Equities analysts anticipate that LivaNova will post 3.77 earnings per share for the current year.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director owned 7,228 shares in the company, valued at $547,521. This represents a 19.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 0.35% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently made changes to their positions in the company. Hantz Financial Services Inc. boosted its holdings in LivaNova by 159.9% in the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after purchasing an additional 267 shares during the period. Public Employees Retirement System of Ohio bought a new position in shares of LivaNova in the 2nd quarter worth about $37,000. State of Wyoming bought a new position in shares of LivaNova in the 2nd quarter worth about $31,000. Quarry LP acquired a new position in shares of LivaNova in the 3rd quarter valued at about $36,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares during the period. 97.64% of the stock is currently owned by institutional investors.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.